Compare Gap Inc (GAP) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs Moderna, Inc. — how do they compare? Gap Inc trades at $20.63 (market cap $7.30B), while Moderna, Inc. trades at $63.81 (market cap $27.09B). The key difference: Moderna, Inc. is far larger — about 3.7× Gap Inc's market cap, and Gap Inc pays a 3.45% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| GAP | MRNA | |
|---|---|---|
Market Cap | $7.30B | $27.09B |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $81.80 |
52-Week Low | $18.35 | $22.36 |
Enterprise Value | $10.38B | $23.19B |
Dividend Yield | 3.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap Inc. (GAP) trades at $20.65, up 2.58% today, with a bullish technical signal supported by oscillators and key resistance at $21. The stock shows strong fundamentals with a P/E of 8.05, net income margin of 6.25%, and consistent earnings beats in recent quarters. Revenue grew to $15.09B in 2025, and operating cash flow remains robust at $1.49B. Recent news highlights digital transformation efforts and a potential turnaround in the Athleta segment.
The outlook is positive with a consensus price target of $27.00, implying 30.7% upside, though risks include ongoing legal investigations and competitive pressures. Analyst sentiment is mixed with 39.58% buy ratings, but improving profitability and undervalued metrics support a constructive view for long-term investors.
Moderna (MRNA) trades at $64.11, down 4.94% over 24 hours, with a bullish technical outlook but mixed fundamentals. The company reported a net loss of -$2.82B in 2025 despite beating EPS estimates in recent quarters. Recent news highlights progress in oncology trials and an EU RSV vaccine contract, fueling investor optimism about pipeline expansion beyond COVID-19 vaccines.
Outlook: Long-term growth depends on successful pipeline commercialization, but high cash burn and negative margins pose risks. Analyst consensus is cautious with a $49 price target, suggesting 23.6% downside. Investors should weigh clinical successes against persistent profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
